stockrowBiofrontera Inc.
BFRI Healthcare Drug Manufacturers Specialty & Generic
Biofrontera Inc.’s revenue for fiscal 2025 (year ended December 2025) was $41.7 million, up 11.7% from fiscal 2024.
- Revenue
- +32.9%
- EPS
- +91.2%
- Free cash flow
- +45.6%
- Total debt
- +6.50%
Quarter to June 2026, against a year earlier
Follow BFRI
Alert me
Biofrontera Inc. (BFRI) EV/Sales
As of 6 November 2026, Biofrontera Inc. (BFRI) trades at a EV/Sales of 0.2×. Over the past ten years it has ranged from −0.6× (September 2022) to 5.7× (December 2021); the current reading is higher than 71% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.9× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.1× | (43.13%) |
| FY2024 | 0.2× | (31.54%) |
| FY2023 | 0.3× | — |
| FY2022 | −0.3× | — |
| FY2021 | 1.7× | (6.27%) |
| FY2020 | 1.8× | 0.00% |
| FY2019 | 1.8× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.3× | 43.77% |
| Mar 2026 | 0.2× | 83.74% |
| Dec 2025 | 0.1× | (68.19%) |
| Sep 2025 | 0.3× | 214.41% |
| 21 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IXHL Incannex Healthcare Inc. compare | −24.1× |
| UPC Universe Pharmaceuticals INC compare | −0.2× |
| OPTH Optimi Health Corp. compare | n/m |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. compare | n/m |
| AYTU Aytu BioPharma, Inc. compare | 0.2× |
| BFRI Biofrontera Inc. | 0.2× |
| CPHI China Pharma Holdings, Inc. compare | 6.2× |
| INM InMed Pharmaceuticals Inc. compare | 15.5× |
| TXMD TherapeuticsMD, Inc. compare | 84.5× |
| Drug Manufacturers Specialty & Generic industry median | 2.9× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)